Press Releases
SABCS15: ONT-380 Phase I results support progression to Phase II in advanced HER2+ breast cancer
Phase I data regarding the experimental cancer agent ONT-380 were presented recently at the 2015 San Antonio Breast Cancer Symposium, indicating initial efficacy in breast cancer patients with metastatic HER2+ breast cancer. The...
Press Releases
Early diagnosis of bowel cancer in the England – Report Highlights
The importance of national screening Data published by Cancer Research UK and Public Health England’s National Cancer Intelligence Network have reported, for the first time & detected through different healthcare. The stages at which bowel...
Press Releases
Updated Label for Daklinza (daclatasvir) for the 12-week Treatment of Non-cirrhotic Patients with Chronic Hepatitis C Genotype 3 Approved by the European Commission
European Commission has approved an updated label for Daklinza for the treatment of genotype 3 chronic hepatitis C (HCV). The update allows the use of Daklinza in combination with sofosbuvir for 12 weeks in patients without cirrhosis in all...
Press Releases
Follow-up Data from Two Pivotal Opdivo (nivolumab) Trials Demonstrates Sustained Survival Results in Patients with Previously Treated Squamous Non-Small Cell Lung Cance
European Commission has approved an updated label for Daklinza for the treatment of genotype 3 chronic hepatitis C (HCV). The update allows the use of Daklinza in combination with sofosbuvir for 12 weeks in patients without cirrhosis in all...
Press Releases
ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients...
The primary endpoints were successfully met in ALLY-1, a Phase III clinical trial evaluating a 12-week regimen of daclatasvir and sofosbuvir once-daily with ribavirin for the treatment of patients with chronic hepatitis C virus (HCV) with either advanced cirrhosis...
Press Releases
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Non-Squamous Non-Small Cell Lung Cancer Patients
Submission based on positive results of the landmark, global Phase 3 study, CheckMate -057 evaluating overall survival versus standard of care in non-squamous non-small cell lung cancer patients U.S. FDA grants application priority review, and Opdivo Breakthrough Therapy Designation...
Press Releases
Bristol-Myers Squibb to Host Investor Teleconference to Discuss World Conference on Lung Cancer (WCLC) Highlights
Bristol-Myers Squibb Company (NYSE:BMY) will host a teleconference on Tuesday, September 8 at 8 a.m. EDT (6 a.m. MDT) to review data presented at the 16th Annual World Conference on Lung Cancer (WCLC) in Denver, CO. ...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read